LRRK2 antibody | knockout validation | Epitomics MJFF2

This is a knockout-validated antibody summary, based on the publications "Detection of endogenous S1292 LRRK2 autophosphorylation in mouse tissue as a readout for kinase activity" [3] (western blot, see supplement figure 1a in the article), "A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation" [1], "LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors" [2] and "LRRK2 modifies α-syn pathology and spread in mouse models and human neurons" for western blot knockout validation (figure s7b) [4]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

LRRK2 antibody | knockout validation | Epitomics MJFF2 figure 1
Figure 1. Western blot of LRRK2 expression in WT and LRRK2 knock-out MEFs. α/β- tubulin was used as loading control. From [1].
Antibody information

Rabbit monoclonal

Company: Epitomics

Antibody: LRRK2

Catalog number: MJFF2, now Abcam ab133474

Summary: Rabbit monoclonal against a recombinant fragment within Human LRRK2 aa 950 to the C-terminus. Reacts with mouse, rat, and human. Suitable for western blot, immunoprecipitation, immunohistochemistry (paraffin and free floating), immunocytochemistry/immunofluorescence.

Article "A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation"
Validation Method

Western blot, Immunohistochemistry

Sample

Mouse skin primary fibroblast cells (MEF) were derived from the dorsal skin of postnatal day 0 (P0) wild-type or Lrrk2 knock-out mouse pups (38). Cells were harvested 24 h post-transfection in buffer containing 50 mm Tris, pH 7.5, 100 mm NaCl, 1% Triton X-100, 1× complete protease inhibitor mixture (Roche), and 1× Halt phosphatase inhibitor mixture (Pierce).

Blocking agent

5% (w/v) skimmed milk in PBS plus 0.1% (v/v) Tween 20 or with 20% (v/v) horse serum in PBS.

Primary incubation

1:2,000 dilution.

Secondary incubation

HRP-conjugated anti-rabbit secondary antibody (Santa Cruz) at a 1:2,000 dilution.

Detection

SuperSignal West Pico Chemiluminescent Substrate (Pierce).

LRRK2 antibody | knockout validation | Epitomics MJFF2 figure 2
Figure 2. Immunohistochemistry with MJFF2 c41-2 antibody showing WT and KO brain sections at the level of the striatum. Specific signal is seen in the WT compared to KO. Rabbit IgG was used as an isotype control. Boxes depict enlarged images to the right. Scale bar 50 microns. From [2].
Article "LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors"
Validation Method

Immunohistochemistry

Sample

Mice brain sections from LRRK2 KO, HET, and WT genotypes. Tissues were formalin fixed, and paraffin embedded.

Blocking agent

Dako All-purpose blocking solution for 30 minutes.

Primary incubation

1:4,000 dilution for 45 min at room temperature.

Secondary incubation

Secondary antibodies from the Envision+ System Labeled Polymer HRP (Dako).

Detection

DAB substrate (Dako).

References
  1. Law B, Spain V, Leinster V, Chia R, Beilina A, Cho H, et al. A direct interaction between leucine-rich repeat kinase 2 and specific ?-tubulin isoforms regulates tubulin acetylation. J Biol Chem. 2014;289:895-908 pubmed publisher
  2. Hinkle K, Yue M, Behrouz B, Dachsel J, Lincoln S, Bowles E, et al. LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol Neurodegener. 2012;7:25 pubmed publisher
  3. Kluss J, Conti M, Kaganovich A, Beilina A, Melrose H, Cookson M, et al. Detection of endogenous S1292 LRRK2 autophosphorylation in mouse tissue as a readout for kinase activity. NPJ Parkinsons Dis. 2018;4:13 pubmed publisher
  4. Bieri G, Brahic M, Bousset L, Couthouis J, Kramer N, Ma R, et al. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons. Acta Neuropathol. 2019;137:961-980 pubmed publisher